Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | Regulatory and commercialization challenges with CAR T-cell therapy

Bruce Levine • 5 Apr 2019
EBMT 2019
General CAR-T

Bruce Levine, PhD, from the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, discusses the challenges regarding regulatory and commercialization of CAR T-cell therapy. Dr Levine was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

More from Bruce Levine

1:26
The impact of COVID-19 on CAR-T therapy
Bruce Levine • 28 May 2020
1:15
CAR-T therapy: where is it going?
Bruce Levine • 28 May 2020
1:20
ISCT 2020: Moving ahead at full speed session - what can delegates look forward to?
Bruce Levine • 28 May 2020
1:00
ISCT 2020: looking forward to advances and emerging technologies in immune-mediated cancer therapy
Bruce Levine • 28 May 2020

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals